Sir,
We thank the authors for their comments on our article "Effect of lanosterol on human cataract nucleus:" [1, 2] • In regard to the comment on mechanisms of cataract formation in congenital and acquired cataracts being different, we agree with the authors and have hi-lighted the same issue in the discussion, quoting Hejtmancik and Kantorow. [3] While it would be appropriate to do this study in the pediatric population, the mechanism of removal of a cataract in the children (lens aspiration) may not allow such a study in vivo, and this would be a major limiting factor to perform such a study • We mirrored our experiment on the one designed by Zhao et al. wherein they had immersed the lens for 6 days.
[4]
While we agree that adult lenses may need to be exposed to lanosterol for longer/higher concentration and have acknowledged the same in the discussion. However, the absolute absence of difference between the control and lanosterol groups at the end of 6 days makes us wonder if changing the concentration or duration would have made any difference to the results • It is possible that our methodology of immersing bare nuclei without the capsule may have impacted the study results, and we have indicated the same in the discussion. However, lanosterol acts by reversing the protein aggregation within the lens fibers and in the absence of the capsule, lanosterol would have better access to the lens fibers and should theoretically have been more effective and not less effective.
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Comment to: Dual effect hypothesis of insulin analogs on diabetic retinopathy
Sir, I read the current review article titled "Does tight control of systemic factors help in the management of diabetic retinopathy?" by Rajalakshmi et al. with great interest.
[1]
Authors present the impact of tight control of systemic factors on progression of diabetic retinopathy (DRP). I congratulate the authors for this lightening review and want to make a contribution.
One of the systemic factors discussed in the article is the glycemic control. Authors stated intensive glycemic control to reduce development and progression of DRP. They also stated that tight glycemic control is most effective when initiated early, but it may at times have adverse effects, including worsening of DRP. According to this statement, tight glycemic control seems to have "dual effect" on progression of DRP that associate with the duration of treatment. We previously hypothesized a mechanism as "dual effect of insulin analogs on progression of DRP" that may explain this phenomenon. [2] As authors addressed in the article, upregulation of insulin-like growth factor-1 (IGF-1) may be the reason of early worsening of DRP. Insulin and its analogs stimulate IGF-1 receptors. Especially some insulin analogs, being developed by changing amino acid chain, are more potent than human insulin. Insulin glargine was reported to be 10 times more potent than human insulin to stimulate IGF-1 receptor.
[3] IGF-1 signaling may cause the progression of DRP. IGF-1 is a receptor of growth hormone (GH). An association between GH and DRP has being known for a long time. DRP regresses after spontaneous infarction or surgical ablation of pituitary gland. [4] In dwarfs, GH deficiency is a protective factor for the development of DRP. [5] Despite the same glycemic control, development of DRP is significantly higher in pubertal subjects than prepubertal subjects.
[6] GH acts on IGF-1 receptor. Insulin analogs also stimulate IGF-1 receptor and may cause progression of DRP through GH-like effect. Insulin analogs may change cellular composition of retina through stimulation of IGF-1 receptors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Author's reply
Sir, We wish to thank the author for reading our article [1] with interest and for the response. [2] We appreciate the author's contribution to the literature, "Dual effect hypothesis of insulin analogues on diabetic retinopathy."
We agree that studies have shown the role of insulin-like growth factor in the pathogenesis of diabetic retinopathy (DR). [3] However, we wish to mention that though there are a few anecdotal reports that some insulin analogs might worsen retinopathy, it has been proven by a randomized controlled trial that there is no evidence of greater risk of the development or progression of DR with insulin glargine. [4] Many established studies such as the Diabetes Control and Complications Trial (DCCT) (Type 1 diabetes) [5] and the Steno Study (Type 2 diabetes) [6] have shown that long-term, intensified intervention aimed at multiple risk factors, particularly glycemic control, reduces the risk for microvascular events, including retinopathy by about 50%. In the long-term follow-up of the DCCT, the Epidemiology of Diabetes Interventions and Complications, the finding that even 7 years after conclusion of the treatment of the DCCT, retinopathy progression in the original "intensive" control group (treated with three times insulin) continued to be much slower than that in the "conventional" treatment group indicates the importance of tight glycemic control in the prevention and management.
Regarding the mention in the letter that Gadkari et al. [7] reported insulin usage as a risk factor for DR in the Indian population, we have also reported similar results in our Chennai Urban Rural Epidemiology Study-Eye Study. [8] The possible explanation is that DR is associated with prolonged uncontrolled hyperglycemia and such patients with Type 2 diabetes are more likely to be treated with insulin along with or without oral hypoglycemic agents (OHA) while those who are under better metabolic control are likely to be continued on OHA. Second, diabetic patients with microvascular IGF-1 has been reported to stimulate and proliferate a type of glial cell named nonastrocytic inner retinal glia-like. [7] Traction force in retinal pigment epithelium and Mullerian cells generates by IGF-1 signaling. [8] Gadkari et al. recently reported insulin usage as a risk factor for progression of DRP in Indian population. [9] Insulin analogs may deteriorate DRP through IGF-1. However, analogs should pass into the retinal tissue to show this effect. Inner blood retinal barrier (IRB) may prevent analogs to pass retinal tissue. When IRB is intact, analogs may not deteriorate DRP through IGF-1 signaling, also protect retina by lowering blood glucose, and prevent harmful effect of hyperglycemia. After impairment of IRB, analogs may pass into the retina and cause progression of DRP by stimulating IGF-1 receptor. We named this mechanism as "dual effect hypothesis of insulin analogs on DRP" that associate with impairment degree of IRB.
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